通讯作者: 宁方玲, ningfangling@126.com

DOI：10.12201/bmr.202605.00079

Antiangiogenic Therapy in First-Line Treatment of Advanced NSCLC: Advances in the Immunotherapy Era

• 摘要：针对驱动基因阴性的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者,免疫检查检查点抑制剂治疗已成为目前指南推荐的一线治疗的重要手段,目前已形成化疗联合免疫治疗作为一线治疗的基础,NSCLC的治疗已正式进入免疫时代。进入免疫治疗时代后,抗血管生成治疗的价值不仅体现在直接抑制肿瘤生长,更在于重塑肿瘤免疫微环境,增强免疫治疗的递送与疗效。首先,我们从分子机制及细胞层面分析了抗血管生成药物用于晚期NSCLC的治疗基础；其次,针对不同目标人群,我们梳理了多项临床研究应用抗血管生成药物联合免疫治疗及化疗对比其他治疗的疗效及安全性分析,并系统回顾了抗血管生成药物,尤其是贝伐珠单抗,在免疫治疗时代下应用于晚期NSCLC一线治疗的循证依据与临床策略。

  关键词： 抗血管生成药物; 晚期非小细胞肺癌#$NBS(NSCLC); 免疫检查点抑制剂(ICIs); 程序死亡配体1(PD-L1)

   

  Abstract: For patients with driver gene-negative advanced non-small cell lung cancer (NSCLC), immune checkpoint inhibitor therapy has become a core first-line treatment recommended by current clinical guidelines. Chemotherapy combined with immunotherapy has been established as the foundation of first-line therapy, marking the official entry of NSCLC treatment into the immunotherapy era. In this context, the value of anti-angiogenic therapy is not only reflected in directly inhibiting tumor growth but also in remodeling the tumor immune microenvironment and enhancing the delivery and efficacy of immunotherapy. This article first systematically elucidates the therapeutic basis of anti-angiogenic agents in advanced NSCLC from the perspectives of molecular mechanisms and cellular levels. Second, focusing on different target populations, it reviews multiple clinical studies evaluating the efficacy and safety of anti-angiogenic agents combined with immunotherapy and chemotherapy. Finally, it systematically summarizes the evidence-based rationale and clinical strategies for the application of anti-angiogenic agents (represented by bevacizumab) in first-line treatment of advanced NSCLC in China during the immunotherapy era, aiming to provide references for individualized clinical decision-making.

  Key words: anti-angiogenic agents; advanced non-small cell lung cancer (NSCLC); immune checkpoint inhibitors (ICIs); programmed death-ligand 1 (PD-L1)

  提交时间：2026-05-22

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 郑歆. PD-1免疫诱导治疗在不可切除Ⅲ期NSCLC中的研究进展. 2025. doi: 10.12201/bmr.202501.00025

  李娜, 罗炳清. 微波消融联合化疗+PD-1抑制剂治疗非小细胞肺癌的临床观察. 2025. doi: 10.12201/bmr.202504.00054

  刘雪杨, 程柯, 许树才. 非小细胞肺癌患者血液高凝状态治疗研究进展. 2025. doi: 10.12201/bmr.202506.00015

  乔明旭, 胡伟. 派安普利联合化疗治疗晚期非鳞非小细胞肺癌的疗效分析. 2025. doi: 10.12201/bmr.202508.00045

  王子婕, 张鑫众. 叶酸受体阳性循环肿瘤细胞与非小细胞肺癌发生发展的研究进展. 2025. doi: 10.12201/bmr.202506.00024

  王亚楠, 王欢, 马莹, 田婧楠, 卢义. 免疫检查点抑制剂相关性甲状腺功能减退的中西医诊疗进展. 2025. doi: 10.12201/bmr.202505.00004

  付思思. 非小细胞肺癌患者肺叶切除术后恶心呕吐Nomogram分析模型构建与验证. 2025. doi: 10.12201/bmr.202507.00001

  吴稚晖, 刘红, 周晓雨, 张茜, 谭年喜. RUNX3、P16和DAPK基因启动子DNA甲基化与非小细胞肺癌化疗敏感性的关系. 2025. doi: 10.12201/bmr.202510.00045

  陈海峰, 钱韵. 免疫检查点抑制剂相关不良反应：临床表现与发生机制. 2025. doi: 10.12201/bmr.202502.00010

  李颖, 王晓妃, 陆圣威, 董丹妮, 张景峰, 郑建军. 免疫检查点抑制剂相关性肺炎CT表现与临床特点分析. 2024. doi: 10.12201/bmr.202407.00008

• 序号	提交日期	编号	操作
  1	2026-04-27	10.12201/bmr.202605.00079V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论